Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Abnormalities in microbiota/butyrate/FFAR3 signaling in aging gut impair brain function
Sidharth P. Mishra, … , Sushil G. Rane, Hariom Yadav
Sidharth P. Mishra, … , Sushil G. Rane, Hariom Yadav
Published February 8, 2024
Citation Information: JCI Insight. 2024;9(3):e168443. https://doi.org/10.1172/jci.insight.168443.
View: Text | PDF
Research Article Aging Microbiology

Abnormalities in microbiota/butyrate/FFAR3 signaling in aging gut impair brain function

  • Text
  • PDF
Abstract

Aging-related abnormalities in gut microbiota are associated with cognitive decline, depression, and anxiety, but underlying mechanisms remain unstudied. Here, our study demonstrated that transplanting old gut microbiota to young mice induced inflammation in the gut and brain coupled with cognitive decline, depression, and anxiety. We observed diminished mucin formation and increased gut permeability (“leaky gut”) with a reduction in beneficial metabolites like butyrate because of decline in butyrate-producing bacteria in the aged gut microbiota. This led to suppressed expression of butyrate receptors, free fatty acid receptors 2 and 3 (FFAR2/3). Administering butyrate alleviated inflammation, restored mucin expression and gut barriers, and corrected brain dysfunction. Furthermore, young mice with intestine-specific loss of FFAR2/3 exhibited gut and brain abnormalities akin to those in older mice. Our results demonstrate that reduced butyrate-producing bacteria in aged gut microbiota result in low butyrate levels and reduced FFAR2/3 signaling, leading to suppressed mucin formation that increases gut permeability, inflammation, and brain abnormalities. These findings underscore the significance of butyrate-FFAR2/3 agonism as a potential strategy to mitigate aged gut microbiota–induced detrimental effects on gut and brain health in older adults.

Authors

Sidharth P. Mishra, Shalini Jain, Bo Wang, Shaohua Wang, Brandi C. Miller, Jea Y. Lee, Cesar V. Borlongan, Lin Jiang, Julie Pollak, Subhash Taraphder, Brian T. Layden, Sushil G. Rane, Hariom Yadav

×

Figure 6

Old microbiota transplantation reduces FFAR2/3 signaling, which attenuates butyrate’s beneficial effect on gut mucin.

Options: View larger image (or click on image) Download as PowerPoint
Old microbiota transplantation reduces FFAR2/3 signaling, which attenuat...
(A) Mice that received old FMT expressed significantly fewer Ffar2 and Ffar3 genes than those that received young FMT. (B–D) Ffar2/3 expression was also significantly reduced in enteroids (B), CMT93 cells (C), and HT29 cells (D) treated with old FCM compared with controls treated with young FCM. (E) Changes recapitulated the suppressed Ffar2/3 expression in the intestine (ileum) of old donors compared with young controls (orange). (F and G) Butyrate (6 μM) significantly increases Ffar2/3 expression in non-FCM and young FCM-treated CMT93 cells and protects from decline in Ffar2/3 expression old FCM-treated cells, while such changes are not seen in acetate-treated groups. (H and I) Inhibiting FFAR2 (using CATPB) and FFAR3 (using siRNA) dampened the positive effects of butyrate treatment on mucin accumulation (PAS staining) (H) and Muc2, Muc6, and Muc13 expression (I) in CMT93 cells, indicating that FFAR2/3 signaling mediates butyrate’s increasing mucin. The original magnification for these images was 4×. All the values represent the mean of 5–10 animals or 3–4 independent replicates from each group in cells and enteroid experiments, repeated 2–3 times, and error bars represent the standard error of means. Statistical significance was determined using t test and/or ANOVA, as applicable, and P values *P < 0.05, **P < 0.01, and ***P < 0.001 are statistically significant.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts